Payment overview · 2025
General Payments
$586.32
36 reported records · 9 companies
Healthcare provider profile · identity verified
David Peter Mouallem, DO
Allopathic & Osteopathic Physicians|Family Medicine · NANTICOKE, PA · NPI 1730132200
Verified facts
What the public records show
CMS Open Payments records show David Peter Mouallem, DO received $586.32 in general payments during 2025 across 36 reported records.
ABBVIE INC. accounted for 30.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 15 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Armour Thyroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 123 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXIUM as an associated drug or biological on 464 records involving 299 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Nexium by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 59 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 74 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 90 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 171 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $178.50 | 30.4% | 9 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $143.68 | 24.5% | 11 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $63.50 | 10.8% | 4 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $57.97 | 9.9% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $36.47 | 6.2% | 2 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $35.11 | 6.0% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $32.29 | 5.5% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $25.18 | 4.3% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $13.62 | 2.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $586.32 | 36 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $170.38 | 7 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $110.75 | 9 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $110.75 | 9 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $66.92 | 5 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $61.65 | 3 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $35.11 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $34.70 | 2 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $32.93 | 2 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $32.93 | 2 | 2025 |
Source payment records
|
|||||
| XGEVA Normalized: xgeva |
Biological | Amgen Inc. | $32.93 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $29.33 | 2 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $28.80 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $28.64 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $13.62 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $13.62 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 171 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 48 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 59 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
123 | 27 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | NEXIUM open payments reported associated product |
CMS Open Payments — General Payments 464 supporting records · 299 recipient NPIs · example record 1206134180 |
Nexium · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
48 | 15 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
59 | 12 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
48 | 15 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
74 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
90 | 15 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
171 | 35 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 893 | 204 |
| Levothyroxine Sodium | Levothyroxine Sodium | 753 | 155 |
| Amlodipine Besylate | Amlodipine Besylate | 544 | 122 |
| Alprazolam | Alprazolam | 416 | 79 |
| Metoprolol Succinate | Metoprolol Succinate | 375 | 80 |
| Lisinopril | Lisinopril | 368 | 85 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 356 | 85 |
| Omeprazole | Omeprazole | 348 | 85 |
| Pantoprazole Sodium | Pantoprazole Sodium | 328 | 66 |
| Furosemide | Furosemide | 324 | 78 |
| Potassium Chloride | Potassium Chloride | 321 | 72 |
| Losartan Potassium | Losartan Potassium | 316 | 75 |
| Famotidine | Famotidine | 293 | 66 |
| Sertraline Hcl | Sertraline Hcl | 278 | 58 |
| Metformin Hcl | Metformin Hcl | 270 | 60 |
| Pravastatin Sodium | Pravastatin Sodium | 234 | 55 |
| Tamsulosin Hcl | Tamsulosin Hcl | 194 | 38 |
| Glimepiride | Glimepiride | 192 | 38 |
| Gabapentin | Gabapentin | 191 | 44 |
| Fluticasone Propionate | Fluticasone Propionate | 185 | 73 |
| Clopidogrel | Clopidogrel Bisulfate | 182 | 39 |
| Valsartan | Valsartan | 181 | 33 |
| Eliquis | Apixaban | 171 | 35 |
| Allopurinol | Allopurinol | 161 | 29 |
| Metoprolol Tartrate | Metoprolol Tartrate | 160 | 38 |
| Methylprednisolone | Methylprednisolone | 148 | 108 |
| Carvedilol | Carvedilol | 139 | 29 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 135 | 52 |
| Hydrochlorothiazide | Hydrochlorothiazide | 132 | 35 |
| Simvastatin | Simvastatin | 128 | 29 |
| Synthroid | Levothyroxine Sodium | 123 | 27 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 122 | 102 |
| Duloxetine Hcl | Duloxetine Hcl | 113 | 23 |
| Prednisone | Prednisone | 107 | 71 |
| Zolpidem Tartrate | Zolpidem Tartrate | 105 | 22 |
| Escitalopram Oxalate | Escitalopram Oxalate | 99 | 21 |
| Ezetimibe | Ezetimibe | 98 | 26 |
| Tradjenta | Linagliptin | 98 | 18 |
| Hydralazine Hcl | Hydralazine Hcl | 95 | 16 |
| Tramadol Hcl | Tramadol Hcl | 93 | 28 |
| Ozempic | Semaglutide | 90 | 15 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 89 | 22 |
| Donepezil Hcl | Donepezil Hcl | 87 | 17 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 86 | 18 |
| Lorazepam | Lorazepam | 84 | 19 |
| Meloxicam | Meloxicam | 84 | 15 |
| Clonazepam | Clonazepam | 83 | 15 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 78 | 19 |
| Ondansetron Hcl | Ondansetron Hcl | 77 | 24 |
| Atenolol | Atenolol | 75 | 19 |
| Baclofen | Baclofen | 75 | 31 |
| Mounjaro | Tirzepatide | 74 | suppressed |
| Azithromycin | Azithromycin | 68 | 52 |
| Fluoxetine Hcl | Fluoxetine Hcl | 67 | 16 |
| Citalopram Hbr | Citalopram Hydrobromide | 66 | 14 |
| Cephalexin | Cephalexin | 62 | 41 |
| Metformin Hcl Er | Metformin Hcl | 62 | 13 |
| Alendronate Sodium | Alendronate Sodium | 61 | 12 |
| Memantine Hcl | Memantine Hcl | 60 | 14 |
| Montelukast Sodium | Montelukast Sodium | 59 | 17 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 59 | 12 |
| Mupirocin | Mupirocin | 57 | 28 |
| Doxycycline Hyclate | Doxycycline Hyclate | 55 | 46 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 54 | 44 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 53 | 35 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 53 | 12 |
| Warfarin Sodium | Warfarin Sodium | 51 | 13 |
| Irbesartan | Irbesartan | 50 | 11 |
| Spironolactone | Spironolactone | 50 | 12 |
| Januvia | Sitagliptin Phosphate | 49 | suppressed |
| Jardiance | Empagliflozin | 48 | 15 |
| Paroxetine Hcl | Paroxetine Hcl | 48 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 46 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 45 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 45 | suppressed |
| Naproxen | Naproxen | 45 | 18 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 45 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 44 | 17 |
| Celecoxib | Celecoxib | 43 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 42 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 41 | 11 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 41 | 11 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 41 | suppressed |
| Finasteride | Finasteride | 40 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 39 | 22 |
| Valacyclovir | Valacyclovir Hcl | 39 | 14 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 38 | suppressed |
| Digoxin | Digoxin | 37 | suppressed |
| Torsemide | Torsemide | 37 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 36 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 36 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 35 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 35 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 34 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 33 | 11 |
| Myrbetriq | Mirabegron | 33 | suppressed |
| Fluticasone Propionate Hfa | Fluticasone Propionate | 32 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 31 | 16 |
| Fenofibrate | Fenofibrate Nanocrystallized | 31 | suppressed |
| Repatha Sureclick | Evolocumab | 31 | suppressed |
| Bupropion Xl | Bupropion Hcl | 30 | suppressed |
| Eszopiclone | Eszopiclone | 30 | suppressed |
| Fluconazole | Fluconazole | 30 | 18 |
| Breo Ellipta | Fluticasone/Vilanterol | 29 | suppressed |
| Repaglinide | Repaglinide | 29 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 29 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 28 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 28 | 16 |
| Mirtazapine | Mirtazapine | 28 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 28 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 27 | 11 |
| Ipratropium Bromide | Ipratropium Bromide | 27 | suppressed |
| Bumetanide | Bumetanide | 26 | suppressed |
| Pregabalin | Pregabalin | 26 | 11 |
| Ramipril | Ramipril | 26 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 25 | suppressed |
| Colchicine | Colchicine | 25 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 25 | suppressed |
| Nystatin | Nystatin | 25 | 20 |
| Ranolazine Er | Ranolazine | 24 | suppressed |
| Tegretol Xr | Carbamazepine | 24 | suppressed |
| Lansoprazole | Lansoprazole | 23 | suppressed |
| Amoxicillin | Amoxicillin | 22 | 11 |
| Nitroglycerin Patch | Nitroglycerin | 22 | suppressed |
| Verapamil Er | Verapamil Hcl | 22 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 21 | suppressed |
| Nateglinide | Nateglinide | 21 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 21 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 21 | suppressed |
| Trulicity | Dulaglutide | 21 | suppressed |
| Cilostazol | Cilostazol | 20 | suppressed |
| Novolog Flexpen | Insulin Aspart | 20 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 20 | suppressed |
| Xarelto | Rivaroxaban | 20 | suppressed |
| Calcitriol | Calcitriol | 19 | suppressed |
| Cefdinir | Cefdinir | 19 | 17 |
| Clotrimazole | Clotrimazole | 19 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 19 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 18 | 11 |
| Dexlansoprazole Dr | Dexlansoprazole | 18 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 18 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 18 | 16 |
| Trazodone Hcl | Trazodone Hcl | 18 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 17 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 17 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 16 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 16 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 16 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 16 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 16 | suppressed |
| Levofloxacin | Levofloxacin | 16 | 12 |
| Methotrexate | Methotrexate Sodium | 16 | suppressed |
| Ibuprofen | Ibuprofen | 15 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 15 | suppressed |
| Aspirin-Dipyridamole Er | Aspirin/Dipyridamole | 14 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 14 | suppressed |
| Nitroglycerin | Nitroglycerin | 14 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 14 | suppressed |
| Risperidone | Risperidone | 14 | suppressed |
| Ampicillin Trihydrate | Ampicillin Trihydrate | 13 | 13 |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 13 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 13 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 13 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 13 | suppressed |
| Zolmitriptan Odt | Zolmitriptan | 13 | suppressed |
| Belsomra | Suvorexant | 12 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 12 | suppressed |
| Cartia Xt | Diltiazem Hcl | 12 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 12 | suppressed |
| Dutasteride | Dutasteride | 12 | suppressed |
| Fosinopril Sodium | Fosinopril Sodium | 12 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 12 | suppressed |
| Klor-Con M20 | Potassium Chloride | 12 | suppressed |
| Methimazole | Methimazole | 12 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 12 | suppressed |
| Nexium | Esomeprazole Magnesium | 12 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 12 | suppressed |
| Topiramate | Topiramate | 12 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 12 | suppressed |
| Armour Thyroid | Thyroid,pork | 11 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 11 | suppressed |
| Entresto | Sacubitril/Valsartan | 11 | suppressed |
| Gemfibrozil | Gemfibrozil | 11 | suppressed |
| Humulin R U-500 Kwikpen | Insulin Regular, Human | 11 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Niacin Er | Niacin | 11 | suppressed |
| Rexulti | Brexpiprazole | 11 | suppressed |
| Sotalol | Sotalol Hcl | 11 | suppressed |
| Tiotropium Bromide | Tiotropium Bromide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $586.32 · 36 records | ABBVIE INC. | AIRSUPRA, AREXVY, BREZTRI, ELIQUIS, EVENITY, JARDIANCE, NURTEC ODT, OTEZLA, PROLIA, QULIPTA, REPATHA, TRELEGY ELLIPTA, UBRELVY, XGEVA, XIFAXAN | 12 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error